ABVD联合局限野放疗治疗I-IIA期霍奇金淋巴瘤无超额长期死亡率
When treating limited stage classical Hodgkin lymphoma (cHL), balancing treatment efficacy and toxicity is important. Toxicities after extended-field radiotherapy are well documented.…
要点
- 中位随访16年,仅2/27例复发发生在5年后
- 与普通人群相比无超额死亡率,仅5年内进展者例外
核心结论
- I-IIA期经典型霍奇金淋巴瘤患者接受ABVD联合30 Gy局限野放疗后无超额长期死亡率。
- 无超额死亡率的结果对短程化疗后省略放疗的策略提出质疑。
研究设计与样本
- 回顾性评估364例1999至2005年间治疗的I-IIA期经典型霍奇金淋巴瘤患者。
- 根据危险因素给予2或4周期ABVD化疗,随后30 Gy局限野放疗(较累及野放疗缩小)。
- 生存随访中位时间为16年。
主要发现
- 5年和10年总生存率分别为98%和96%。
- 27例复发中仅2例发生在5年之后。
- 与普通人群相比无超额死亡率;亚组分析中仅5年内进展患者显示显著超额死亡率。
关键数值与推荐
- 放疗剂量为30 Gy局限野(较累及野放疗缩小)。
- 化疗方案为ABVD,周期数根据危险因素选择2或4周期。
- 5年总生存率98%,10年总生存率96%。
- 中位随访16年,27例复发中仅2例在5年后发生。
临床怎么用
- 对于I-IIA期经典型霍奇金淋巴瘤,ABVD联合30 Gy局限野放疗可获得优异的长期生存且无超额死亡率。
- 短程化疗后省略放疗的策略需谨慎评估,因其可能与复发风险升高相关。
局限性
- 原文未报告研究类型为回顾性还是前瞻性。
- 原文未报告对照组的设置情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
When treating limited stage classical Hodgkin lymphoma (cHL), balancing treatment efficacy and toxicity is important. Toxicities after extended-field radiotherapy are well documented. Investigators have aimed at reducing toxicity without compromising efficacy, mainly by using combined modality treatment (CMT), i.e. chemotherapy and limited-field radiotherapy. In some clinical trials, radiotherapy has been omitted. We evaluated 364 patients with stage I-IIA cHL treated between 1999 and 2005. Patients were treated with two or four cycles of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) according to presence of risk factors, followed by 30 Gy limited-field (reduced compared to involved-field) radiotherapy. After a median follow-up of 16 years for survival, freedom from progression at five and ten years was 93% and overall survival at 5 and 10 years was 98% and 96%, respectively. Only two relapses, out of 27, occurred after more than 5 years. There was no excess mortality compared to the general population. Of the analysed subgroups, only patients with progression within five years showed significant excess mortality. The absence of excess mortality questions the concept of omitting radiotherapy after short-term chemotherapy, a strategy that has been associated with an elevated risk of relapse but not yet with a proven reduced long-term excess mortality.
引用
- Lagerlöf I, Holte H, Glimelius I, et al. No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. Br J Haematol. 2019. PMID: 31612478. doi:10.1111/bjh.16232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。